In vitro effects of cholecystokinin fragments on human gallbladders. Evidence for an altered CCK-receptor structure in a subgroup of patients with gallstones

Journal of Hepatology

Volumn 26, Issue 5, 1997, Pages 1063-1068

  Schneider, Harald ^a   Sänger, Philip ^a   Hanisch, Ernst ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

CCK fragment; Cholecystokinin (CCK); Cholecystolithiasis; Gallbladder motility; Receptor alteration

Indexed keywords

CHOLECYSTOKININ; CHOLECYSTOKININ RECEPTOR;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; GALLBLADDER MOTILITY; GALLBLADDER MUCOSA; GALLSTONE; GALLSTONE FORMATION; HUMAN; HUMAN TISSUE; INFLAMMATION; PATHOGENESIS; PRIORITY JOURNAL; RECEPTOR DENSITY; SMOOTH MUSCLE CONTRACTILITY;

EID: 0343376464     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(97)80115-8     Document Type: Article

References (27)

1. Eysselein V, Reeve J, Shively J, Hawke D, Walsh J. Partial structure of a large canine cholecystokinin. Peptides. 3:1982;687-691.
2. Mutt V, Jorpes J. Structure of porcine cholecystokinin-pancreozymin. Eur J Biochem. 6:1968;156-162.
3. Eng J, Du B, Pan YC, Chang M, Hulmes J, Yalow R. Purification and sequencing of a rat intestinal 22 amino acid C-terminal CCK fragment. Peptides. 5:1984;1203-1206.
4. Dockray G. Immunoreactive component resembling cholecystokinin octapeptide in intestine. Nature. 270:1977;357-361.
5. Reeve J, Eysselein V, Walsh J, Sankaran J, Deveney C, Tourtellotte W, Miller C, Shively J. Isolation and characterization of biologically active and inactive cholecystokinin-octapeptides from human brain. Peptides. 5:1984;959-966.
6. Rehfeld J, Larsson L. The predominating molecular form of gastrin and cholecystokinin in the gut is a small peptide corresponding to their COOH-terminal tetrapeptide amide. Acta Physiol Scand. 105:1979;117-119.
7. Dockray G, Gregory R. Does the C-terminal tetrapeptide of gastrin and CCK exist as an entity? Nature. 286:1980;742-748.
8. Ryan J, Cohen S. Interaction of gastrin, secretin and cholecystokinin on gallbladder smooth muscle. Am J Physiol. 230:1976;553-556.
9. Behar J, Biancani P. Effect of cholecystokinin and octapeptide of cholecystokinin on feline sphincter of Oddi and gallbladder mechanisms of action. J Clin Invest. 66:1980;1231-1239.
10. Ondetti M, Rubin B, Engel S, Pluscec J, Sheehan T. Cholecystokinin-pancreozymin: Recent developments. Dig Dis. 15:1970;149-156.
11. Lamers C, Poitras W, Jansen J, Walsh J. Relative potencies of cholecystokinin-33 and cholecystokinin-8 measured by radioimmunoassy and bioassay. Scand J Gastroenterol. 18:1983;191-192. (Suppl 83).
12. Schjoldager B, Molero X, Miller LJ. Functional and biochemical characterization of the human gallbladder muscularis cholecystokinin receptor. Gastroenterology. 96:1989;1119-1125.
13. Pisegna JR, de Weerth A, Wank SA. Molecular cloning of the human brain and gastric cholecystokinin receptor: structure, functional expression and chromosomal localization. Biochem Biophys Res Commun. 189:1992;296-303.
14. Wank SA, Pisegna JR, de Weerth A. Brain and gastrointestinal cholecystokinin receptor family: structure and functional expression. Proc Natl Acad Sci USA. 89:1992;8912-8917.
15. Upp JR, Nralon WH, Singh P, Fagan CJ, Jonas AS, Greely GH, Thompson JC. Correlation of cholecystokinin receptors with gallbladder contractilityin patients with gallstones. Ann Surg. 205:1987;641-648.
16. Maggi CA, Barbanti G, Turini D, Guilani S. Effect of NG-monomethyl-L-arginine (L-NO-Arg) non-adrenergic non-cholinergic relaxation in the circular muscle of the human ileum. Br J Pharmacol. 103:1991;1070-1072.
17. Karaki H, Weiss G. Calcium channels in smooth muscle. Gastroenterology. 87:1984;960-970.
18. Lotti VJ, Pendleton RG, Gould RJ, Hanson HM, Chang RSL, Clineschmidt BV. In vivo pharmacology of L-364,718, a new potent nonpeptide peripheral cholecystokinin antagonist. J Pharmacol Exp Ther. 241:1987;103-109.
19. Lotti VJ, Cerino DJ, Kling PJ, Chang RSL. A new simple mouse model for the in vivo evaluation of cholecystokinin (CCK) antagonists: comparative potencies and duration of action of nonpeptide antagonists. Life Sci. 39:1986;1631-1638.
20. Kenakin T. Pharmacologic Analysis of Drug-Receptor Interaction. 1993;Raven Press, New York.
21. Corsi M, Palea S, Pietra C, Oliosi B, Gaviraghi G, Sugg E. A further analysis of the contraction induced by activation of the cholecystkinin A receptors in guinea pig isolated ileum longitudinal muscles-myenteric plexus. J Pharm Exp Ther. 270:1994;734-740.
22. Behar J, Rhim BY, Thompson W, Biancani P. Inositol trisphosphate restores impaired human gallbladder motility associated with cholesterol stones. Gastroenterology. 104:1993;563-568.
23. Bobba VR, Krishnamurty GT, Kingston E, Turner FE, Brown PH, Langrell K. Gallbladder dynamics induced by a fatty meal in normal subjects and patients with gallstones: Concise communication. J Nucl Med. 25:1984;21-24.
24. Forgacs IC, Maisey MN, Murphy GM, Dowling RH. Influence of gallstones and ursodeoxycholic acid therapy on gallbladder emptying. Gastroenterology. 87:1984;299-307.
25. Schulz M, Hanisch E, Güldütüna S. In vitro Kontraktilitätsverhalten humaner Muskulatur von Gallenblasen mit und ohne Steinerkrankungen-Relevanz des Prostaglandinsystems für die CCK-regulierte Motorik. Z Gastroenterol. 31:1993;376-387.
26. Ulrich CD, Ferber I, Holicky E, Hadac E, Buell G, Miller JL. Molecular cloning and functional expression of the human gallbladder cholecystokinin A receptor. Biochem Biophys Res Commun. 183/1:1993;204-211.
27. de Weerth A, Pisegna JR, Huppi K, Wank SA. Molecular cloning, functional expression and chromosomal localization of the human cholecystokinin type A receptor. Biochem Biophys Res Commun. 194/2:1993;811-818.